Valuation
- Market cap
- 344,892,000
- Revenue TTM
- $0
- Net income TTM
- $-165,670,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 3,046,400
- Avg volume
- 1,225,830
- Day's range
- $3.02 – $3.34
- Shares out
- 103,883,000
- Stochastic %K
- 5%
- Beta
- 0.74
- Analysts
- Strong Sell
- Price target
- $14.40
Company profile
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 844 511 9056
- Website
- https://www.larimartx.com
- Address
- Three Bala Plaza East, Suite 506, Bala Cynwyd, United States
Latest news
No headlines yet.
